Risk factors
Absci (ABSI) risk factors
Item 1A of every Absci Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors83 risks19 new16 dropped23 reworded
Absci faces escalating financial losses, accumulating $624.8M by late 2025 while expanding its proprietary and partnered therapeutic drug pipelines.
Filed Mar 24, 2026 - FY2024 10-K risk factors80 risks
Absci faces heavy concentration risk with two partners driving 99% of its partner program revenue in 2024. The company has a limited operating history and an accumulated deficit of $509.6 million. Operations depend entirely on the success of its Integrated Drug Creation platform and synthetic biology technologies.
Filed Mar 18, 2025